117 related articles for article (PubMed ID: 20608887)
1. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence.
Mauskopf JA; Baker CL; Monz BU; Juniper MD
J Med Econ; 2010; 13(3):403-17. PubMed ID: 20608887
[TBL] [Abstract][Full Text] [Related]
2. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ
J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
[TBL] [Abstract][Full Text] [Related]
5. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
García Ruiz AJ; Leiva Fernández F; Martos Crespo F
Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions.
Neyt M; Devriese S; Thiry N; Van den Bruel A
BMC Pulm Med; 2010 Sep; 10():47. PubMed ID: 20843311
[TBL] [Abstract][Full Text] [Related]
8. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
Friedman M; Menjoge SS; Anton SF; Kesten S
Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
[TBL] [Abstract][Full Text] [Related]
9. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
Oba Y
Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore.
Lee KH; Phua J; Lim TK
Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566
[TBL] [Abstract][Full Text] [Related]
12. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease].
Schramm W; Haake D; Brandt A
Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.
Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N
Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084
[TBL] [Abstract][Full Text] [Related]
14. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.
Rutten-van Mölken MP; Goossens LM
Pharmacoeconomics; 2012 Apr; 30(4):271-302. PubMed ID: 22409290
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.
Somand H; Remington TL
Ann Pharmacother; 2005 Sep; 39(9):1467-75. PubMed ID: 16030078
[TBL] [Abstract][Full Text] [Related]
18. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system.
Onukwugha E; Mullins CD; DeLisle S
Value Health; 2008; 11(5):980-8. PubMed ID: 18194405
[TBL] [Abstract][Full Text] [Related]
19. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
Gani R; Griffin J; Kelly S; Rutten-van Mölken M
Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
